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Abstract 
The fact that you can vaccinate a child at 5 years of age and find lymphoid B cells and 
antibodies specific for this vaccination 70 years later remains an immunological enigma. It 
has never been determined how these long-lived memory B cells are maintained and 
whether they are protected by storage in a special niche. We report that, whereas blood and 
spleen compartments present similar frequencies of IgG+ cells, anti-smallpox memory B 
cells are specifically enriched in the spleen where they account for 0.24% of all IgG+ cells, 
i.e. 10-20 million cells, more than 30 years after vaccination. They represent in contrast 
only 0.07% of circulating IgG+ B cells in blood, i.e. 50-100,000 cells. An analysis of 
patients either splenectomized or rituximab-treated confirmed that the spleen is a major 
reservoir for long-lived memory B cells. No significant correlation was observed between 
the abundance of these cells in blood and serum titers of anti-vaccinia virus antibodies in 
this study, including in the contrasted cases of B-cell depleting treatments. Altogether, 
these data provide evidence that in humans, the two arms of B cell memory -long-lived 
memory B cells and plasma cells- have specific anatomical distributions -spleen and bone 
marrow- and homeostatic regulation.  
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Introduction 
Long-lived memory B cells and specific antibodies have been reported to persist in the 
body for decades after specific vaccination.1-3 One of the central questions concerning this 
phenomenon concerns the maintenance of this memory in the absence of repeated 
stimulations with the original vaccine. Experiments in mice suggested that the survival of 
memory B cells depended neither on constant cell proliferation nor on the presence of the 
immunizing antigen.4,5 It was therefore assumed that these cells remain quiescent for long 
periods of time, but nonetheless react very rapidly if they encounter the immunizing 
antigen. It has also been suggested that the presence of specific serum antibodies is directly 
linked to the presence of the corresponding memory B cells. In this model, each new 
antigenic stimulation provides bystander T cell help for the previously generated memory B 
cells, leading to the differentiation of some of these cells into Ig-secreting plasmocytes.6 An 
alternative explanation for the continued presence of serum antibodies a long time after the 
initial pathogen encounter has also been put forward, according to which each vaccination 
induces both the immediate differentiation of plasmocytes and the formation of long-lived 
plasma cells.7,8 These memory plasma cells would survive in bone marrow and would be 
replaced, at a certain rate, by plasmablasts generated in response to new pathogens.9 
Smallpox vaccination is considered an ideal model for studies of the basis of long-term 
cellular and humoral memory.10 Vaccinia virus was successfully used to eradicate variola 
virus, the etiologic agent of smallpox. As smallpox vaccination was stopped in the mid 
1970s and smallpox was eradicated worldwide in 1977,11 we can assume that people have 
not been re-exposed to the pathogen since then. Using ELISPOT assays following in vitro 
cell stimulation, we studied the maintenance of the vaccinia virus-specific memory B cell 
pool in the blood and spleen of normal individuals, and in those of patients who had 
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undergone B cell-targeted immune interventions. We show here that long-lived memory B 
cells have their own central reservoir, the spleen, and seem to display their own 
homeostatic regulation, independent of the presence of the corresponding plasmocytes. 
 
Materials and Methods 
Viruses 
The modified vaccinia virus Ankara (MVA), which was used as the antigen in the B-cell 
ELISPOT assay, was amplified in chicken embryo fibroblasts and purified by 
centrifugation on a sucrose cushion. Alternatively, highly purified MVA preparations for 
use in ELISA were produced by centrifugation on two successive sucrose gradient 
cushions. Titers were determined by plaque assays on confluent chicken embryo fibroblast 
monolayers grown in six-well tissue culture plates.12  
 
Patients and controls 
Approval for this research was granted by the “Comité de protection des personnes Ile-de-
France II”. Written informed consent was obtained from all patients. The characteristics of 
the subjects, including age, sex, diagnosis and medication taken at the time of sample 
collection are detailed in Supplemental Tables S1-S3. Nine splenectomized patients (V10 to 
V18: 4 benign and 3 malignant pancreatic tumors, 2 idiopathic thrombocytopenic purpura, 
ITP) displayed normal numbers of B cells and had not undergone any chemotherapy. Nine 
rituximab-treated patients (RTX1 to RTX9) suffered chronic ITP, Sjogren’s syndrome or 
non-Hodgkin’s lymphoma. Rituximab regimen is detailed in Supplemental Table S2 (3 
patients received light corticotherapy). Chemotherapy treatment, when given (RTX3, 
RTX4), was stopped at least 25 months before sample collection, except for V19. Bone 
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marrow samples were obtained from diagnosis aspirations. For all patients, B cell content 
and proportions of IgG+ B cells are detailed in Supplemental Tables S1-S3. As a control, 
we obtained blood samples from 16 healthy subjects from the blood bank (Etablissement 
Français du Sang): 9 vaccinated individuals (35 to 59 years old) and 7 non-vaccinated 
individuals (all under the age of 28 years). Control spleens were retrieved after splenectomy 
of non-vaccinated patients (microspherocytosis and physical trauma, 7 and 17 year-old 
respectively).  
 
Isolation of cells and serum 
Spleen samples were recovered in complete medium (RPMI-1640, 100 mU/ml penicillin, 
100 µg/ml streptomycin (all from Invitrogen) and 10% fetal calf serum (FCS, HyClone, 
Logan, UT) after surgery and were stored at 4°C until processing. In some cases, the entire 
spleen was maintained under physiological perfusion for 6 h before cell isolation, as 
described by Buffet et al.,13 with no influence in results. Cell suspensions were obtained by 
mechanical dissociation in complete medium. Peripheral blood and bone marrow aspirates 
were collected in heparin or EDTA tubes for cell isolation. In all experiments, mononuclear 
cells (MNC) from blood, bone marrow aspirates or spleen cell suspensions were isolated by 
centrifugation on a Ficoll-Hypaque density gradient. Red blood cells were lysed and the 
remaining cells were washed with 2% FCS in PBS and resuspended in complete medium 
containing 50 µM β-mercaptoethanol. Cell viability after isolation was determined by 
counting with Trypan Blue exclusion and only samples with viability exceeding 90% were 
considered. In the case of patient RTX6 (B cell content below 1%), the splenic preparation 
was enriched for B cells, using the B cell-negative isolation kit (Dynal-Biotech, Oslo, 
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Norway) according to the manufacturer’s recommendations. Such enrichment was 
performed in order to obtain a measurable value in ELISPOT assay. Serum was prepared 
by clotting blood collected in SST tubes (BD Diagnosis, Franklin Lakes, NJ) or by treating 
one volume of plasma with one volume of BC thrombin reagent (Dade Behring, Marburg, 
Germany) for 10 min at room temperature. Serum was then inactivated by heating for 30 
min at 56°C and frozen in aliquots.  
 
Flow cytometry 
Cells were routinely labelled with the following antibodies: fluorescein isothiocyanate 
(FITC)-conjugated rabbit F(ab’)2 anti-human IgG (F0056) or the corresponding isotype 
control (X0929) from Dako (Glostrup, Denmark), phycoerythrin (PE)-conjugated anti-
human CD27 antibody (clone 1A4-CD27) and PE-cyanin 5.1 (PC5)-anti human CD19 
antibody (clone J4.119) from Beckman-Coulter (Fullerton, CA), allophycocyanin (APC) 
anti-CD19 (clone HIB19) from BD Pharmingen (San Diego, CA). When indicated, labelled 
cells were incubated with 7-AAD (BD Pharmingen) 10 minutes before analysis in order to 
exclude dead cells. Cells were analyzed on a FACScan or FACSCalibur, with CellQuest 
Pro software (BD Biosciences, San Diego, CA).   
 
Memory B cell assay 
This procedure was adapted from that described by Crotty et al.14 Briefly, PBMC or MNC 
were plated at 5 x 105 cells /ml in 24-well (5 x 105 cells) or 6-well (5 x 106 cells) plates, in 
complete culture medium supplemented with 10 ng/ml pokeweed mitogen extract (PWM, 
batch 1303H, ICN, MP Biomedicals, Aurora, OH), a 1/10,000 dilution of fixed 
Staphylococcus aureus, Cowan extract (SAC, Sigma-Aldrich, St-Louis, MO) and 6 µg/ml 
 - 7 - 
fully phosphothioated CpG (ODN-2006,15 Proligo-Sigma-Aldrich). Cells were cultured for 
six days at 37°C, under an atmosphere containing 5% CO2. They were then washed and 
used to seed 96-well plates: from each culture well of 5 x 105 cells, 1/5 of the cells were 
used for IgG ELISPOT and 4/5 were used for MVA or KLH ELISPOT. From culture wells 
of 5 x 106 cells, 1/20 was used for IgG ELISPOT and 19/20 was used for MVA or KLH 
ELISPOT. Samples were serially diluted in culture medium, in triplicate, before transfer to 
ELISPOT plates. Multiscreen 96-well filter plates (MSIPS4510, Millipore, Bedford, MA) 
were coated by incubation overnight at 4°C with 100 µl of 3 x 108 MVA pfu /ml, 2.5 µg/ml 
keyhole limpet hemocyanin (KLH, Pierce Biochemicals) or 10 µg/ml anti-human Ig 
polyvalent antibody (Caltag Laboratories, Burlingame, CA). ELISPOT was performed with 
1 µg/ml biotinylated goat anti-human IgG Fc (H10015, Caltag Laboratories) followed by 5 
µg/ml HRP-conjugated Avidin D (Vector Laboratories, Burlingam, CA) and developed 
using 3-amino-9-ethylcarbazole (Sigma-Aldrich). Spots were counted in wells showing 
more than 3 specific spots, in an ELISPOT reader, with AID software (version 3.5, 
Autoimmun Diagnostika GmbH, Germany). When detected, IgG secreting cell numbers 
from the corresponding unstimulated wells (cells cultivated in complete medium alone) 
were substracted to the values obtained in stimulated cells. Each experiment was conducted 
in 3 independent wells and the results are the mean of the 3 ELISPOT values obtained. 
Data are presented as the percentage of total IgG+ memory B cells specific for vaccinia 
virus. When no vaccinia virus-specific spot was detectable, a value of <x was assigned, 
with x corresponding to the frequency obtained if one vaccinia-specific spot was detected at 
the lowest dilution.  
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ELISA 
Maxisorp plates (Nunc, Roskilde, Denmark) were coated by incubation overnight at 4°C 
with 106 MVA pfu/well. Plates were blocked by incubation with 10% FCS in PBS for 1 h at 
37°C. Triplicates of serum samples were serially diluted in PBS-0.05% Tween20 (PBST) 
and incubated for 1 h at 37°C. Plates were washed four times in PBST, and were then 
incubated for 1 h at 37°C with peroxidase-conjugated goat anti-human IgG Fc (Nordic 
Immunology, Tilburg, The Netherlands) at a concentration of 2 µg/ml in PBST. Plates were 
washed four times in PBST and incubated with OPD (Sigmafast OPD tablets, Sigma-
Aldrich) for 10 min at room temperature. The reaction was stopped by adding 1.8 N H2SO4, 
and optical density was measured at a wavelength of 490 nm. The determination of serum 
titer is detailed in Supplemental Figure S1. 
 
Statistical Methods 
Non parametric Kruskal-Wallis two-sided score test was used to compare the frequency of 
vaccinia virus-specific memory B cells between blood and spleen and between controls and 
splenectomized patients, as well as serum titers of vaccinia virus antibody between the 
different groups studied. For the 23 vaccinated individuals for whom both parameters were 
known, we estimated the Spearman coefficient of correlation R2 between anti-vaccinia virus 
antibody titers and the frequency of vaccinia virus-specific memory B cells. All analyses 
were performed using SAS Software 9.1 (SAS Institute, Cary, NC). 
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Results 
Anti-vaccinia virus memory B cells are concentrated in the spleen 
We first compared the proportion of memory B cells against vaccinia virus in the blood and 
spleen several decades after vaccination, in samples obtained from vaccinated (Table 1, V1-
V20) or non-vaccinated (Table 1, C1-C9) individuals. The modified vaccinia virus Ankara 
(MVA) is a replication-deficient strain of vaccinia virus that was tested as a safer vaccine 
for smallpox vaccination.16 It was used throughout this study for the ELISPOT and ELISA 
assays, to assess cellular and serological anti-smallpox/vaccinia virus memory. Blood or 
splenic mononuclear cells were analyzed by ELISPOT against MVA, after 6 days of in 
vitro polyclonal stimulation, as described by Crotty et al.14 We determined the proportion 
of anti-vaccinia virus-specific B cells as the ratio of anti-MVA IgG+ cells to total IgG+ cells 
(Figure 1A). The members of the vaccinated cohort were aged between 31 and 75 years, 
whereas the non-vaccinated controls were all under the age of 28 years (Table 1). We first 
confirmed previous results,1 showing that a median of 0.07% of circulating IgG+ memory B 
cells were specific for vaccinia virus in the blood of individuals vaccinated more than 30 
years previously, with the values observed lying between 0.01 and 0.16% (Figure 1B; Table 
1). The absence of anti-vaccinia virus memory B cells in the non-vaccinated controls 
indicated an absence of cross-reactive responses induced by closely related viruses. We 
retrieved splenic fragments, mostly from patients who had undergone surgery for a 
pancreatic tumor (see description of patients in Supplemental Table S1). Splenic 
mononuclear cells from nine patients vaccinated at least 30 years ago, and from two non-
vaccinated controls (7 and 17 years old) were analyzed with the anti-MVA ELISPOT assay. 
The proportion of anti-vaccinia virus memory B cells in the spleen was much higher, at 
0.24%, with values ranging from 0.07 to 0.62% (Figure 1B; V10-V18 in Table 1). No 
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vaccinia virus-specific IgG secreting cells were detected in control culture with 
unstimulated cells either from blood or from spleen. In three patients from whom both 
splenic and blood samples could be obtained, the proportion of memory B cells in the 
spleen and blood differed by a factor of three to ten (Figure 1B insert; V10, V13, V18, in 
Table 1), these differences being observed even in cases in which the frequency of splenic 
memory B cell was in the lower range (Table 1, V13 and V18).  
 
Variable impact of rituximab-induced B cell depletion on anti-vaccinia virus memory 
B cell survival 
It has been reported that the circulation is depleted of most of its B cells following 
treatment with rituximab, a B cell-depleting anti-CD20 antibody. However, the extent of 
this depletion seems to be more variable in lymphoid organs.17-19 B cell recovery in the 
blood starts about six months after the end of the treatment, with normal levels reached 
after 12 to 20 months. We analyzed the blood of five patients treated with rituximab 25 to 
39 months previously (Table 2; Figure 1C). No circulating anti-vaccinia virus memory B 
cells were detected in two patients (RTX3: <0.007%, RTX5: <0.04%), whereas such cells 
were detected in two others (RTX4, RTX1), albeit at a low frequency (0.01 and 0.04%). 
Surprisingly, in the last patient (RTX2), memory B cells specific for vaccinia virus were 
found 26 months after rituximab treatment (RIT; 2 cycles, see description of patients in 
Supplemental Tables S2) at a frequency much higher (0.32%) than that observed in the 
blood of normal individuals analyzed several decades after vaccination. An increase in 
serum B-cell-activating factor (BAFF) concentration has been reported after RIT in some 
patients.20 Serum BAFF level was normal in patient RTX2 (not shown), leaving us with no 
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clear explanation for these findings. Thus, most patients treated with rituximab displayed a 
lower frequency of anti-vaccinia virus memory B cells in their blood.  
 
Some splenic anti-vaccinia virus memory B cells can resist rituximab treatment 
Given the highly variable pattern of memory B cell recovery after RIT, and assuming that 
the spleen could act as a major reservoir for these cells, we decided to determine the 
frequency of residual memory B cells in the spleen after RIT. We focused on three cases of 
idiopathic thrombocytopenic purpura (ITP) who underwent splenectomy after a failure to 
respond to treatment. One patient (RTX6, Table 2) was splenectomized three months after 
RIT. No B cells were detected in his blood and the percentage of B cells in the spleen was 
very low (around 0.1%). These cells were found to be almost exclusively IgG+ CD27+ 
(Figure 2), thus suggesting a memory phenotype. After in vitro stimulation, anti-vaccinia 
virus memory B cells were detected, amounting to 0.14% of total IgG+ B cells (Table 2). 
The second patient (RTX7, Table 2) underwent splenectomy six months after the end of 
RIT. B cells were beginning to reappear in his blood (1.6%, versus 10% in controls) and 
spleen (10% versus 40% in controls). Memory B cells against vaccinia virus were not 
detectable in his blood and amounted to 0.06% in his spleen. In the third patient (RTX8, 
Table 2) in which the spleen was retrieved 15 months after the end of RIT, B cells 
recovered to normal values in blood and spleen (Supplemental Table S2) but vaccinia 
virus-specific memory B cells could only be found in the spleen at a frequency of 0.06% of 
total IgG secreting cells. These three cases evoke that a small pool of splenic anti-vaccinia 
virus memory B cells (a few tens of thousands memory B cells) have resisted to RIT along 
with other IgG+ switched B cells. As the spleen replenishes with newly formed IgG+ B 
cells, this pool may tend to dilute itself.  
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Splenectomy affects the circulating long-lived memory B cell pool 
If long-lived memory B cells are principally maintained in the spleen, then the frequency of 
these cells should be significantly lower in patients that have been splenectomized several 
years ago. We collected blood samples from five patients, who had undergone splenectomy 
7 to 50 years previously (see description of patients in supplemental Table S3). The levels 
of circulating anti-vaccinia virus memory B cells were all below the median of the control 
values (Figure 1C; Table 2, SPL4: no detectable anti-vaccinia virus memory B cells, SPL1: 
0.01%, SPL3: 0.009%, SPL2, for which small accessory spleens were detected: 0.04% and 
SPL5: 0.06%). These results suggest that splenectomy may lead to a consistent loss of 
long-lived memory B cells and that this deficiency can persist even several decades after 
the surgical procedure. Nevertheless, these cells can still be found, albeit at diminished 
levels, in the blood of most of these patients, suggesting the existence of other minor 
storage sites outside the spleen.  
Further evidence to support this hypothesis is provided by the case of a rituximab-treated 
patient who underwent splenectomy two months after four cycles of RIT and who was 
analyzed 36 months after splenectomy. A small proportion of circulating anti-vaccinia virus 
memory B cells could be detected in this patient (RTX9: 0.02%, Table 2).  
In two cases in which it was possible to analyze a bone marrow sample not contaminated 
with malignant cells or blood, we detected no significant enrichment of anti-vaccinia virus 
memory B cells over average values for blood (V19: 0.04%, V20: 0.02%, Table 1). 
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No significative correlation between vaccinia virus-specific serum antibody titers and 
blood memory B cells 
We estimated the correlation between the proportion of memory B cells and the level of 
specific antibodies against vaccinia virus, by using ELISA to determine serum anti-vaccinia 
virus antibody titers in the blood of most of the subjects analyzed in this study (Tables 1 
and 2). A large proportion of the patients vaccinated more than 30 years ago had 
measurable levels of anti-vaccinia virus antibodies, consistent with the findings of previous 
reports.1-3 We took a value of 0.075, the median value for non-vaccinated individuals, as 
the threshold below which levels of IgG against vaccinia virus were considered negative 
(Table 1 and Supplemental Figure S1). Three patients with no anti-vaccinia virus antibodies 
were found to have vaccinia virus-specific memory B cells in their blood (V6, Table 1 and 
RTX4, SPL5, Table 2). Conversely, in three patients with a reasonably high level of anti-
vaccinia virus antibodies, no circulating anti-vaccinia virus memory B cells could be 
detected in their blood (V13, Table 1 and SPL4, RTX3, Table 2). No significative 
correlation was found in this study between the proportion of memory B cells and the titer 
of antibodies specific for vaccinia virus (Figure 3, for n=23 individuals, R2=-0.03, 
p-value=0.88). 
 
Discussion  
We studied the persistence of vaccinia virus-specific memory B cells in the blood and 
spleen of normal individuals and of patients who had undergone B cell-targeted immune 
interventions, splenectomy or anti-CD20 mediated B cell depletion. 
In individuals vaccinated with the vaccinia virus during their childhood (i.e., more than 30 
years before this study) about 0.24% of splenic IgG+ B cells recognize this pathogen. This 
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proportion is significantly higher than that for the blood (about 0.07%, consistent with 
previous reports1,3). Taking into account the size of the blood and splenic B cell 
compartments (approximately 5x108 and 4x1010 B cells respectively, with 10 to 20% IgG+ 
B cells), there are, on average, around 0.5 to 1 x 105 memory B cells against vaccinia virus 
circulating in the blood of vaccinated individuals, and 1 to 2 x 107 such cells in the spleen. 
Assuming that all pathogens display similar numbers of immunodominant B cell epitopes, 
thereby engaging similar numbers of memory B cells, this suggests that the splenic B cell 
compartment has an overall memory against 102 to 103 different pathogens. The values 
proposed for the repertoire of long-lived plasma cells in humans are of the same order of 
magnitude.21 It has been suggested that some long-lived plasma cells may be regularly 
replaced by newly formed plasmablasts, although it remains unclear how this replacement 
takes place.9 A similar turnover may occur for memory B cells, but again, we know little of 
the basic mechanism of memory formation and the signals conferring on these cells a 
shorter or longer existence within the individual.  
We could not study lymph nodes or Peyer’s patches from vaccinated individuals, raising 
questions about the possibility of other secondary lymphoid organs constituting an 
additional reservoir for long-lived memory B cells. There was a severe reduction, although 
not a complete loss, of circulating anti-vaccinia virus memory B cells in most 
splenectomized patients. This suggests that these cells survive as such in the blood or that 
there are other accessory niches outside the spleen. Rituximab, a chimeric human/mouse 
anti-CD20 antibody, has become a major treatment for B cell-related lymphomas and 
autoimmune disorders. Two to four years after RIT, most patients presented much lower 
levels of circulating anti-vaccinia virus memory B cells. Analysis of the spleen a few 
months after RIT showed the presence of residual B cells, with the IgG+ phenotype only, 
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including a small proportion of long-lived memory B cells, despite the total absence of 
circulating B cells. Strikingly, a low level of circulating anti-vaccinia virus memory B cells 
was also observed in one patient, three years after a splenectomy performed 2 months after 
the completion of rituximab treatment. Since B cell depletion was still complete in the 
blood at the time of splenectomy, this unique case strengthens the view that there are other 
storage sites for memory B cells, but that these sites do not seem to compensate 
quantitatively for the absence of the spleen. Bone marrow has been identified as a 
preferential niche for long-lived plasma cells and for some memory T and B cells.7,8,22,23 
We did not detect any specific enrichment of vaccinia virus memory B cells in the two bone 
marrow samples that we have analyzed. Overall, these results suggest that the spleen is a 
major niche for long-lived memory B cells but that despite drastic B cell depleting 
treatment such as RIT or splenectomy, these cells can slowly reappear in the blood. These 
treatments therefore do not seem to result in the systematic eradication of the B cell 
memory carried by these patients, notably the one related to childhood vaccinations. 
Consistent with this interpretation, the response to recall antigens seemed to be strongly 
decreased by rituximab treatment in one study of lymphoma patients,24 whereas this 
response was found to be preserved in another study.25  
The concept of two layers of long-term humoral memory sustained by the existence of 
long-lived memory B cells and long-lived plasma cells emerged some years ago7,8 and has 
subsequently been strongly supported by experimental data.26 It has also been proposed that 
the maintenance of antibodies several decades after a vaccination or an infection was due to 
a constant production by non specific stimulation of memory B cells.6 In the later case, 
there should be a quantitative correlation between the frequency of memory B cells and the 
level of serum antibodies. In several reports in which these parameters were analyzed after 
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vaccination or natural infections, the strength of the correlation varied considerably,1,3,27-29 
suggesting that bystander stimulation of memory B cells into short lived plasma cells was 
unlikely to be a general mechanism. In the present study, in which it was possible to 
analyze more strongly contrasting situations, no correlation was observed for the 23 
patients for whom both serum titers of anti-vaccinia virus antibodies and memory B cells 
could be determined. In fact, a complete dissociation was observed in several cases, with 
anti-vaccinia virus antibodies detected in the total absence of the corresponding memory B 
cells, or memory B cells being present in the absence of the corresponding antibodies. This 
observation gives additional support to the proposal that long-lived memory B cells and 
long-lived plasma cells in humans are independent entities, with long-lived plasma cells 
able to survive for several decades independently of the presence of memory B cells of the 
same specificity.3,8,30 Nevertheless, B cell memory does not seem to be a uniform 
phenomenon and one can not exclude that some antigen-specific or non specific stimulation 
of long-lived memory B cell could also contribute to the production of antibodies.6,31  
Many unanswered questions remain concerning the homeostatic regulation of long-lived 
memory B cells. If the spleen is indeed, as proposed here, a main reservoir for these cells, 
then most memory B cells may only react to a specific recall pathogen once it reaches the 
spleen, whereas the circulating memory B cells and neutralizing antibodies will provide a 
first line of defense at the beginning of infection. 
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Table 1. Serum anti-vaccinia virus antibodies and anti-vaccinia virus memory B cells 
in blood, spleen and bone marrow 
% vaccinia virus-specific  
memory B cells 
Individual Age 
(years) 
Anti-vaccinia 
virus IgG 
(serum dilution 
ratio)† 
 
In blood 
 
In spleen 
In bone 
marrow 
Non-vaccinated      
C1 28 0.22 <0.001*   
C2 27 0.07 <0.001*   
C3 24 nd <0.013*   
C4 24 0.04 <0.030*   
C5 23 0.12 <0.010*   
C6 20 0.08 <0.004*   
C7 20 0.05 <0.010*   
C8 17 nd <0.018* <0.002* 
 
C9 7 nd nd <0.005* 
 
Median  0.075    
 
Vaccinated 
     
V1 59 0.27 0.037   
V2 56 0.28 0.110   
V3 53 1 0.088   
V4 53 0.38 0.112   
V5 53 0.10 0.134   
V6 48 0.07 0.062   
V7 48 0.49 0.010   
V8 45 nd 0.117   
V9 35 0.73 0.155   
V10 75 1.16 0.047 0.456  
V11 74 0.53 nd 0.157  
V12 66 ni nd 0.309  
V13 59 0.40 <0.012* 0.068  
V14 58 0.29 nd 0.301  
V15 57 nd nd 0.616  
V16 53 nd nd 0.230  
V17 45 0.21 nd 0.238  
V18 31 ni 0.031 0.088  
V19 53 0.68 0.022  0.038 
V20 47 0.10 0.067  0.018 
Median  0.380  0.067  0.238  
*Maximum estimate for individuals for whom memory B cells were undetectable (see the 
Methods section), †Dilution factor with respect to the positive control, see definition in the 
Materials and Methods section, nd: not done, ni: not interpretable (patient receiving 
intravenous Ig at the time of sample collection). 
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Table 2. Serum anti-vaccinia virus antibodies and anti-vaccinia virus memory B cells 
in rituximab-treated (RTX) and splenectomized (SPL) patients 
% vaccinia virus-specific 
memory B cells 
Patient Age at 
sample 
collection 
Time after 
rituximab  
(months) 
Anti-vaccinia 
virus IgG 
(serum dilution 
ratio) 
In blood In spleen 
RTX1 83 39 0.12 0.044  
RTX2 61 26 0.84 0.317  
RTX3 55 29 0.32 <0.007*  
RTX4 45 25 0.05 0.010  
RTX5 42 32 0.25 <0.041*  
RTX6 79 3 ni -† 0.140 
RTX7 70 6 ni -† 0.063 
RTX8 62 15 0.47 -† 0.064 
RTX9 67 2 + 36≠ 0.40 0.015 
 
Patient Age at 
sample 
collection 
Years after 
splenectomy 
Anti-vaccinia 
virus IgG 
(serum dilution 
ratio) 
% vaccinia virus-specific 
memory B cells in blood 
SPL1 60 50 1.10 0.010 
SPL2 59 44 0.20 0.041 
SPL3 52 7 0.34 0.009 
SPL4 46 35 0.28 <0.009* 
SPL5 35 30 0.01 0.062 
*Maximum estimate for individuals for whom memory B cells were undetectable. †B cell 
depletion precluded blood analyses. ≠Patient was splenectomized 2 months after rituximab 
treatment. Blood was collected 36 months after splenectomy. Other definitions as in Table 
1, see clinical description in Supplemental Tables S2-S3. 
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Figure Legends 
 
Figure 1. Vaccinia virus-specific memory B cells are enriched in the spleen and 
decreased in blood after splenectomy or rituximab treatment.  
ELISPOT assays were performed after 6 days of in vitro polyclonal stimulation of 
mononucleated cells. (A) ELISPOT showing a 10-fold enrichment of anti-vaccinia memory 
B cells in the spleen. MVA, anti-IgG or an unrelated antigen (KLH) were used as coating 
antigens. Blood and spleen samples from patient V10 (Table 1). Shown is one 
representative ELISPOT well out of three, corresponding to the indicated dilution for each 
antigen. (B) Frequency of anti-vaccinia virus memory B cells in blood and spleen, 
determined by ELISPOT assay. The insert shows data from three patients (V10, V13, V18, 
Table 1) for whom both blood and spleen were analyzed. (C) Frequency of anti-vaccinia 
virus memory B cells determined by ELISPOT assay in blood of splenectomized (SPL) and 
rituximab-treated (RTX) patients, compared to healthy donors (Control, same samples as in 
panel B). Bold lines indicate the median values for groups with sample size >5. Dashed 
symbols correspond to maximum estimates for individuals for whom specific memory B 
cells were undetectable (see Materials and Methods). p are determined by a non parametric 
Kruskal-Wallis two-sided test. 
 
Figure 2. Rituximab-resistant splenic B cells are CD27+IgG+.  
The B cell content was analyzed at the time of splenectomy, three months after four cycles 
of rituximab (patient RTX6, Table 2). (A) CD19 and CD27 staining of blood PBMC. (B) 
Staining of the splenic MNC. From left to right: 7-AAD staining; CD19 and CD27 staining 
gated on 7-AAD-negative cells; IgG and isotype control staining of CD19-positive 
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7-AAD-negative cells. 80% of the splenic CD19+ B cells were of the IgG+CD27+ memory 
phenotype.  
 
Figure 3. No correlation between anti-vaccinia virus antibodies and memory B cells in 
blood.  
Anti-vaccinia virus IgG titer and anti-vaccinia virus memory B cell frequency from the 
same blood samples were compared. Data are from n=23 individuals including 12 control 
individuals (circles), 5 splenectomized patients (diamonds) and 6 rituximab-treated patients 
(triangles) for whom both values were measurable. Dashed symbols correspond to 
maximum estimates for individuals for whom memory B cells were undetectable (see 
Materials and Methods) and anti-vaccinia virus serum titer were positive. Shown is the 
Spearman coefficient of correlation R2 for the n=23 samples (p-value=0.88). 
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